TY - JOUR
T1 - External Validation of the Michigan Barrett's Esophagus Prediction Tool
AU - Thrift, Aaron P.
AU - Vaughan, Thomas L.
AU - Anderson, Lesley A.
AU - Whiteman, David C.
AU - El-Serag, Hashem B.
N1 - This work was supported by the National Institutes of Health R01 CA116845 (HES); K24-04-107 (HES); an Ireland–Northern Ireland cooperation research project grant sponsored by the Northern Ireland Research and Development Office and the Health Research Board, Ireland (for FINBAR; RES/1699/01N/S); the Study of Digestive Health, NCI RO1 CA 001833 (DCW); the Study of Reflux Disease, NCI R01 CA72866 (TLV); and the Established Investigator Award in Cancer Prevention and Control, K05 CA124911 (TLV).
PY - 2017/7
Y1 - 2017/7
N2 - Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those with chronic gastroesophageal reflux disease (GERD) and at least 2 risk factors (eg, >50 years of age, white race, obese, tobacco smoking history).2, 3 However, providing clinicians with a tool that allows them to estimate a patients’ risk may better aid them in deciding who to screen for BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well between men with and without BE, with an area under the receiver-operating characteristic curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 vs 0.61; P < .001).4 However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice.
AB - Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those with chronic gastroesophageal reflux disease (GERD) and at least 2 risk factors (eg, >50 years of age, white race, obese, tobacco smoking history).2, 3 However, providing clinicians with a tool that allows them to estimate a patients’ risk may better aid them in deciding who to screen for BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well between men with and without BE, with an area under the receiver-operating characteristic curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 vs 0.61; P < .001).4 However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85020645680&partnerID=8YFLogxK
UR - https://pureadmin.qub.ac.uk/ws/portalfiles/portal/125653230/CGH_D_17_00043_r1_clean.pdf
U2 - 10.1016/j.cgh.2017.03.004
DO - 10.1016/j.cgh.2017.03.004
M3 - Article
C2 - 28300685
AN - SCOPUS:85020645680
SN - 1542-3565
VL - 15
SP - 1124
EP - 1126
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 7
ER -
